Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 6th Society of Hematologic Oncology (SOHO) Italy Annual Conference was held on February 25-26, 2025, in Rome, Italy, and virtually. This meeting brought together experts to discuss the latest in hematologic cancers.

SOHO Italy 2025

25–26 February 2025 | Rome, Italy

SOHO Italy 2025

25–26 February 2025 | Rome, Italy
The 6th Society of Hematologic Oncology (SOHO) Italy Annual Conference was held on February 25-26, 2025, in Rome, Italy, and virtually. This meeting brought together experts to discuss the latest in hematologic cancers.
The current management of extramedullary disease and plasma cell leukemia 2:36
The current management of extramedullary disease and plasma cell leukemia
Daniele Derudas • 3 Mar 2025
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies 5:04
Strategies being explored to enhance the efficacy of CAR T-cells in hematological malignancies
Massimiliano Mazza • 26 Feb 2025
The diagnosis of extramedullary disease and plasma cell leukemia 1:58
The diagnosis of extramedullary disease and plasma cell leukemia
Daniele Derudas • 3 Mar 2025
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma 3:04
Optimizing reporting of infection rates in clinical trials of bispecific antibodies in myeloma
Joshua Richter • 4 Mar 2025
Novel strategies being explored to improve outcomes for patients with EMD or PCL 1:45
Novel strategies being explored to improve outcomes for patients with EMD or PCL
Daniele Derudas • 3 Mar 2025
LINKER-MM1 trial update and the potential approval of linvoseltamab for R/R myeloma 1:33
LINKER-MM1 trial update and the potential approval of linvoseltamab for R/R myeloma
Hans Lee • 26 Feb 2025
Looking to the future of CNS lymphoma management 1:36
Looking to the future of CNS lymphoma management
Andrés Ferreri • 28 Feb 2025
Novel agents for the treatment of CLL in Italy 2:06
Novel agents for the treatment of CLL in Italy
Antonio Cuneo • 27 Feb 2025
Toxicities associated with BCMA, GPRC5D & FcRH5-targeting bispecifics and advice on their management 2:46
Toxicities associated with BCMA, GPRC5D & FcRH5-targeting bispecifics and advice on their management
Joshua Richter • 4 Mar 2025
Challenges in the treatment of multiple myeloma in Brazil 2:18
Challenges in the treatment of multiple myeloma in Brazil
Angelo Maiolino • 26 Feb 2025
The standard of care for newly diagnosed AL amyloidosis and promising agents in the R/R space 1:46
The standard of care for newly diagnosed AL amyloidosis and promising agents in the R/R space
Hans Lee • 26 Feb 2025
Managing early relapses in multiple myeloma: bispecifics, ADCs & CAR-T 2:58
Managing early relapses in multiple myeloma: bispecifics, ADCs & CAR-T
Joshua Richter • 4 Mar 2025
What lies ahead for bispecifics in multiple myeloma? 2:02
What lies ahead for bispecifics in multiple myeloma?
Joshua Richter • 4 Mar 2025
The current standard approach to myeloma treatment in Brazil 2:36
The current standard approach to myeloma treatment in Brazil
Angelo Maiolino • 26 Feb 2025
The current role of brentuximab vedotin in Hodgkin lymphoma 1:34
The current role of brentuximab vedotin in Hodgkin lymphoma
Amanda Cashen • 25 Feb 2025
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma 1:47
The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma
Amanda Cashen • 25 Feb 2025
The content of VJHemOnc is intended for healthcare professionals